Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Can-Fite BioPharma ( (CANF) ) has issued an announcement.
On January 27, 2025, Can-Fite BioPharma Ltd. announced that its lead drug candidate, Namodenoson, received a patent from the US Patent Office for use as an anti-obesity drug. This patent, set to expire in 2042, covers the oral administration of Namodenoson for treating obesity. Namodenoson has shown promising results in reducing fat levels and body weight in experimental models and human studies. The patent strengthens Can-Fite’s position in the rapidly growing anti-obesity industry, projected to reach significant revenue by 2030, and supports the ongoing development of Namodenoson for various medical conditions.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company in the advanced clinical stage of drug development, focusing on oncological and inflammatory diseases. The company is known for its pipeline of proprietary small molecule drugs and is targeting major markets in cancer, liver, and inflammatory disease treatments.
YTD Price Performance: -12.85%
Average Trading Volume: 456,551
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.92M
For an in-depth examination of CANF stock, go to TipRanks’ Stock Analysis page.
